Search

Your search keyword '"Fortpied, Catherine"' showing total 189 results
Start Over Author "Fortpied, Catherine"
189 results on '"Fortpied, Catherine"'

1. Stereotactic Body Radiotherapy for Centrally Located Inoperable Early-Stage NSCLC: EORTC 22113–08113 LungTech Phase II Trial Results

Author

Levy, Antonin, Adebahr, Sonja, Hurkmans, Coen, Ahmed, Merina, Ahmad, Shahreen, Guckenberger, Matthias, Geets, Xavier, Lievens, Yolande, Lambrecht, Maarten, Pourel, Nicolas, Lewitzki, Victor, Konopa, Krzysztof, Franks, Kevin, Dziadziuszko, Rafal, McDonald, Fiona, Fortpied, Catherine, Clementel, Enrico, Fournier, Béatrice, Rizzo, Stefania, Fink, Christian, Riesterer, Oliver, Peulen, Heike, Andratschke, Nicolaus, McWilliam, Alan, Gkika, Eleni, Schimek-Jasch, Tanja, Grosu, Anca-Ligia, Le Pechoux, Cécile, Faivre-Finn, Corinne, and Nestle, Ursula

Published
2024
Full Text
View/download PDF

2. Acute toxicity in patients with oligometastatic cancer following metastasis-directed stereotactic body radiotherapy: An interim analysis of the E2-RADIatE OligoCare cohort

Author

Alongi, Filippo, Nicosia, Luca, Ricardi, Umberto, Scorsetti, Marta, Greto, Daniela, Balermpas, Panagiotis, Lievens, Yolande, Braam, Pètra, Jereczek-Fossa, Barbara Alicja, Stellamans, Karin, Ratosa, Ivica, Simek, Inga-Malin, Peulen, Heike, Dirix, Piet, Verbeke, Luc, Ramella, Sara, Hemmatazad, Hossein, Khanfir, Kaouthar, Geets, Xavier, Jeene, Paul, Zilli, Thomas, Fournier, Beatrice, Fortpied, Catherine, Boakye Oppong, Felix, Ost, Piet, and Guckenberger, Matthias

Published
2024
Full Text
View/download PDF

3. Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: An interim analysis of the EORTC-ESTRO E2-RADIatE OligoCare study

Author

Christ, Sebastian M., Alongi, Filippo, Ricardi, Umberto, Scorsetti, Marta, Livi, Lorenzo, Balermpas, Panagiotis, Lievens, Yolande, Braam, Pètra, Jereczek-Fossa, Barbara Alicja, Stellamans, Karin, Ratosa, Ivica, Widder, Joachim, Peulen, Heike, Dirix, Piet, Bral, Samuel, Ramella, Sara, Hemmatazad, Hossein, Khanfir, Kaouthar, Geets, Xavier, Jeene, Paul, Zilli, Thomas, Fournier, Beatrice, Ivaldi, Giovanni Battista, Clementel, Enrico, Fortpied, Catherine, Oppong, Felix Boakye, Ost, Piet, and Guckenberger, Matthias

Published
2024
Full Text
View/download PDF

4. Health-related quality of life in men with oligometastatic prostate cancer following metastases-directed stereotactic body radiotherapy: Real-world data from the E2-RADIatE OligoCare cohort

Author

Bultijnck, Renée, Van Hemelrijck, Mieke, Fonteyne, Valérie, Livi, Lorenzo, Jereczek-Fossa, Barbara Alicja, Hemmatazad, Hossein, Mayinger, Michael, Peulen, Heike, Verbeke, Luc, Ramella, Sara, Castro, Pablo, Tsoutsou, Pelagia, Stellamans, Karin, Shaukat, Adnan, Orazem, Miha, Jeene, Paul, Braam, Pètra, Verkooijen, Helena, Simek, Inga-Malin, Alongi, Filippo, Clementel, Enrico, Fortpied, Catherine, Machingura, Abigirl, Boakye Oppong, Felix, Guckenberger, Matthias, and Ost, Piet

Published
2024
Full Text
View/download PDF

6. A Quality Control Study on Involved Node Radiation Therapy in the European Organisation for Research and Treatment of Cancer/Lymphoma Study Association/Fondazione Italiana Linfomi H10 Trial on Stages I and II Hodgkin Lymphoma: Lessons Learned

Author

Aleman, Berthe M.P., Ricardi, Umberto, van der Maazen, Richard W.M., Meijnders, Paul, Beijert, Max, Boros, Angela, Izar, Françoise, Janus, Cécile P.M., Levis, Mario, Martin, Valentine, Specht, Lena, Corning, Coreen, Clementel, Enrico, Raemaekers, John M., André, Marc P., Federico, Massimo, Fortpied, Catherine, and Girinsky, Theodore

Published
2023
Full Text
View/download PDF

7. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group

Author

Lacas, Benjamin, Carmel, Alexandra, Landais, Cécile, Wong, Stuart J, Licitra, Lisa, Tobias, Jeffrey S, Burtness, Barbara, Ghi, Maria Grazia, Cohen, Ezra EW, Grau, Cai, Wolf, Gregory, Hitt, Ricardo, Corvò, Renzo, Budach, Volker, Kumar, Shaleen, Laskar, Sarbani Ghosh, Mazeron, Jean-Jacques, Zhong, Lai-Ping, Dobrowsky, Werner, Ghadjar, Pirus, Fallai, Carlo, Zakotnik, Branko, Sharma, Atul, Bensadoun, René-Jean, Redda, Maria Grazia Ruo, Racadot, Séverine, Fountzilas, George, Brizel, David, Rovea, Paolo, Argiris, Athanassios, Nagy, Zoltán Takácsi, Lee, Ju-Whei, Fortpied, Catherine, Harris, Jonathan, Bourhis, Jean, Aupérin, Anne, Blanchard, Pierre, Pignon, Jean-Pierre, Group, MACH-NC Collaborative, Adelstein, DJ, Alfonsi, M, Belkacemi, Y, Bar-Ad, V, Bernier, J, Bratland, Å, Calais, G, Campbell, B, Caudell, J, Chabaud, S, Chamorey, E, Chaukar, D, Choi, KN, Choussy, O, Collette, L, Cruz, JJ, Dani, C, Dauzier, E, Forastiere, AA, Garaud, P, Gregoire, V, Hackshaw, A, Haddad, E, Haffty, BG, Hansen, A, Hayoz, S, Horiot, JC, Jeremic, B, Karrison, TG, Langendijk, JA, Lapeyre, M, Lartigau, E, Leong, T, Le, QT, Lee, PPY, Lewin, F, Lin, A, Lopes, A, Mehta, S, Moon, J, Moyal, E, Occéan, BV, Olmi, P, Orecchia, R, O'Sullivan, B, Overgaard, J, Petit, C, Quon, H, Sanguineti, G, Satar, T, Simes, J, Simon, C, Sire, C, Staar, S, Stromberger, C, Strojan, P, Temam, S, Thomson, D, Timochenko, A, Torri, V, and Tseroni, V

Subjects
Cancer, Clinical Trials and Supportive Activities, Rare Diseases, Clinical Research, 6.5 Radiotherapy and other non-invasive therapies, Evaluation of treatments and therapeutic interventions, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell, Chemotherapy, Adjuvant, Head and Neck Neoplasms, Humans, Induction Chemotherapy, Randomized Controlled Trials as Topic, Meta-analysis, Review, Individual Patient Data, Randomised Clinical Trials, Chemotherapy, Radiotherapy, Head and Neck Cancer, MACH-NC Collaborative Group, Other Physical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Background and purposeThe Meta-Analysis of Chemotherapy in squamous cell Head and Neck Cancer (MACH-NC) demonstrated that concomitant chemotherapy (CT) improved overall survival (OS) in patients without distant metastasis. We report the updated results.Materials and methodsPublished or unpublished randomized trials including patients with non-metastatic carcinoma randomized between 1965 and 2016 and comparing curative loco-regional treatment (LRT) to LRT + CT or adding another timing of CT to LRT + CT (main question), or comparing induction CT + radiotherapy to radiotherapy + concomitant (or alternating) CT (secondary question) were eligible. Individual patient data were collected and combined using a fixed-effect model. OS was the main endpoint.ResultsFor the main question, 101 trials (18951 patients, median follow-up of 6.5 years) were analyzed. For both questions, there were 16 new (2767 patients) and 11 updated trials. Around 90% of the patients had stage III or IV disease. Interaction between treatment effect on OS and the timing of CT was significant (p

Published
2021

8. Mapping the location of local and regional recurrences according to breast cancer surgery and radiation therapy: Results from EORTC 22922/10925

Author

Kaidar-Person, Orit, Giasafaki, Peggy, Boersma, Liesbeth, De Brouwer, Peter, Weltens, Caroline, Kirkove, Carine, Peignaux-Casasnovas, Karine, Budach, Volker, van der Leij, Femke, Vonk, Ernest, Weidner, Nicola, Rivera, Sofia, van Tienhoven, Geertjan, Fourquet, Alain, Noel, Georges, Valli, Mariacarla, Guckenberger, Matthias, Koiter, Eveline, Racadot, Severine, Abdah-Bortnyak, Roxolyana, Bartelink, Harry, Struikmans, Henk, Fortpied, Catherine, and Poortmans, Philip M.

Published
2023
Full Text
View/download PDF

9. Reply to T. Vassilakopoulos et al

Author

Federico, Massimo, primary, Plattel, Wouter, additional, Hutchings, Martin, additional, Stepanishyna, Yana, additional, Fortpied, Catherine, additional, and André, Marc, additional

Published
2024
Full Text
View/download PDF

10. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis

Author

Adelstein, D.J., Agarwal, J., Alfonsi, M., Argiris, A., Aupérin, A., Bacigalupo, A., Bar-Ad, V., Bartelink, H., Beadle, B., Belkacemi, Y., Bensadoun, R.J., Bernier, J., Blanchard, P., Bourhis, J., Bratland, Å., Brizel, D., Budach, V., Budach, W., Burtness, B., Calais, G., Campbell, B., Caudell, J., Chabaud, S., Chamorey, E., Chaukar, D., Cheugoua-Zanetsie, M., Cho, K.H., Choussy, O., Cruz Hernandez, J.J., Denham, J.W., Dobrowsky, W., Dominello, M.M, Driessen, C.M.L., Fallai, C., Forastiere, A.A., Fortpied, C., Fountzilas, G., Garaud, P., Garden, A.S., Gery, B., Ghadjar, P., Ghi, M.G., Ghosh Laskar, S., Graff-Cailleaud, P., Grau, C., Gregoire, V., Hackshaw, A., Haddad, E, Haffty, B.G., Hansen, A., Hay, J.H., Hayoz, S., Horiot, J.C., Hitt, R., Jeremic, B., Johansen, J., Jones, C., Julieron, M., Kristensen, C.A., Kumar, S., Lacas, B., Langendijk, J.A., Lapeyre, M., Lartigau, E., Licitra, L., Le, Q.T., Lee, J.W., Lee, P., Lewin, F., Li, Y., Lopes, A., Lotayef, M., Maciejewski, B., Mazeron, J.J., Mehta, S., Michalski, W., Moon, J., Moon, S.H., Moyal, E., Nankivell, M., Nilsson, P., Olmi, P., Orecchia, R., O'Sullivan, B., Overgaard, J., Parmar, M.K.B., Petit, C., Pignon, J.P., Pointreau, Y., Posner, M.R., Poulsen, M.G., Quon, H., Racadot, S., Rosenthal, D.I., Rovea, P., Ruo Redda, M.G., Sanguineti, G., Shenouda, G., Simes, J., Sharma, A., Simon, C., Sire, C., Skladowski, K., Spencer, S., Staar, S., Strojan, P., Stromberger, C., Suwinski, R., Szutkowski, Z., Takácsi-Nagy, Z., Tao, Y.G., Temam, S., Thomson, D., Tobias, J.S., Torres-Saavedra, P., Torri, V., Tripcony, L., Trotti, A., Tseroni, V., van Herpen, C., van Tinteren, H., Vermorken, J., Viegas, C.M.P., Vokes, E.E., Waldron, J., Wernecke, K.D, Widder, J., Wolf, G.T., Wong, S.J., Wu, J.S., Yamazaki, H., Zaktonik, B., Zackrisson, B., Zhong, L.P., Petit, Claire, Lacas, Benjamin, Pignon, Jean-Pierre, Le, Quynh Thu, Grégoire, Vincent, Grau, Cai, Hackshaw, Allan, Zackrisson, Björn, Parmar, Mahesh K B, Lee, Ju-Whei, Ghi, Maria Grazia, Sanguineti, Giuseppe, Temam, Stéphane, Cheugoua-Zanetsie, Maurice, O'Sullivan, Brian, Posner, Marshall R, Vokes, Everett E, Cruz Hernandez, Juan J, Szutkowski, Zbigniew, Lartigau, Eric, Budach, Volker, Suwiński, Rafal, Poulsen, Michael, Kumar, Shaleen, Ghosh Laskar, Sarbani, Mazeron, Jean-Jacques, Jeremic, Branislav, Simes, John, Zhong, Lai-Ping, Overgaard, Jens, Fortpied, Catherine, Torres-Saavedra, Pedro, Bourhis, Jean, Aupérin, Anne, and Blanchard, Pierre

Published
2021
Full Text
View/download PDF

11. Internal mammary and medial supraclavicular lymph node chain irradiation in stage I–III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial

Author

Poortmans, Philip M, Weltens, Caroline, Fortpied, Catherine, Kirkove, Carine, Peignaux-Casasnovas, Karine, Budach, Volker, van der Leij, Femke, Vonk, Ernest, Weidner, Nicola, Rivera, Sofia, van Tienhoven, Geertjan, Fourquet, Alain, Noel, Georges, Valli, Mariacarla, Guckenberger, Matthias, Koiter, Eveline, Racadot, Severine, Abdah-Bortnyak, Roxolyana, Van Limbergen, Erik F, Engelen, Antoine, De Brouwer, Peter, Struikmans, Henk, and Bartelink, Harry

Published
2020
Full Text
View/download PDF

13. Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma

Author

Federico, Massimo, primary, Fortpied, Catherine, additional, Stepanishyna, Yana, additional, Gotti, Manuel, additional, van der Maazen, Richard, additional, Cristinelli, Caterina, additional, Re, Alessandro, additional, Plattel, Wouter, additional, Lazarovici, Julien, additional, Merli, Francesco, additional, Specht, Lena, additional, Schiano de Colella, Jean-Marc, additional, Hutchings, Martin, additional, Versari, Annibale, additional, Edeline, Véronique, additional, Stamatoulas, Aspasia, additional, Girinsky, Theodore, additional, Ricardi, Umberto, additional, Aleman, Berthe, additional, Meulemans, Bart, additional, Tonino, Sanne, additional, Raemaekers, John, additional, and André, Marc, additional

Published
2023
Full Text
View/download PDF

14. Season of radiotherapy and outcomes of head & neck cancer patients in the MACH-NC & MARCH meta-analyses

Author

LIMKIN, Elaine, primary, BLANCHARD, Pierre, additional, LACAS, Benjamin, additional, BOURHIS, Jean, additional, PARMAR, Mahesh, additional, LICITRA, Lisa, additional, LE, Quynh-Thu, additional, YOM, Sue, additional, FORTPIED, Catherine, additional, LANGENDIJK, Johannes, additional, VERMORKEN, Jan B, additional, BERNIER, Jacques, additional, OVERGAARD, Jens, additional, HARRIS, Jonathan, additional, PIGNON, Jean-Pierre, additional, and AUPERIN, Anne, additional

Published
2023
Full Text
View/download PDF

15. Supplementary Data_Figures 1 from Tumor Microenvironment Modifications Induced by Afatinib in Squamous Cell Carcinoma of the Head and Neck: A Window-of-Opportunity Study (EORTC-90111–24111)

Author

Beyaert, Simon P., primary, Loriot, Axelle E., primary, Huyghe, Nicolas D., primary, Goebbels, Rose-Marie, primary, Mendola, Antonella, primary, Govaerts, Anne-Sophie, primary, Fortpied, Catherine, primary, Baldin, Pamela, primary, Licitra, Lisa F., primary, Lalami, Yassine, primary, Clement, Paul M., primary, Machiels, Jean-Pascal H., primary, and Schmitz, Sandra, primary

Published
2023
Full Text
View/download PDF

16. Tables 3 from Tumor Microenvironment Modifications Induced by Afatinib in Squamous Cell Carcinoma of the Head and Neck: A Window-of-Opportunity Study (EORTC-90111–24111)

Author

Beyaert, Simon P., primary, Loriot, Axelle E., primary, Huyghe, Nicolas D., primary, Goebbels, Rose-Marie, primary, Mendola, Antonella, primary, Govaerts, Anne-Sophie, primary, Fortpied, Catherine, primary, Baldin, Pamela, primary, Licitra, Lisa F., primary, Lalami, Yassine, primary, Clement, Paul M., primary, Machiels, Jean-Pascal H., primary, and Schmitz, Sandra, primary

Published
2023
Full Text
View/download PDF

17. Data from Tumor Microenvironment Modifications Induced by Afatinib in Squamous Cell Carcinoma of the Head and Neck: A Window-of-Opportunity Study (EORTC-90111–24111)

Author

Beyaert, Simon P., primary, Loriot, Axelle E., primary, Huyghe, Nicolas D., primary, Goebbels, Rose-Marie, primary, Mendola, Antonella, primary, Govaerts, Anne-Sophie, primary, Fortpied, Catherine, primary, Baldin, Pamela, primary, Licitra, Lisa F., primary, Lalami, Yassine, primary, Clement, Paul M., primary, Machiels, Jean-Pascal H., primary, and Schmitz, Sandra, primary

Published
2023
Full Text
View/download PDF

18. Tables 2 from Tumor Microenvironment Modifications Induced by Afatinib in Squamous Cell Carcinoma of the Head and Neck: A Window-of-Opportunity Study (EORTC-90111–24111)

Author

Beyaert, Simon P., primary, Loriot, Axelle E., primary, Huyghe, Nicolas D., primary, Goebbels, Rose-Marie, primary, Mendola, Antonella, primary, Govaerts, Anne-Sophie, primary, Fortpied, Catherine, primary, Baldin, Pamela, primary, Licitra, Lisa F., primary, Lalami, Yassine, primary, Clement, Paul M., primary, Machiels, Jean-Pascal H., primary, and Schmitz, Sandra, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Data - "Tables 1" from Tumor Microenvironment Modifications Induced by Afatinib in Squamous Cell Carcinoma of the Head and Neck: A Window-of-Opportunity Study (EORTC-90111–24111)

Author

Beyaert, Simon P., primary, Loriot, Axelle E., primary, Huyghe, Nicolas D., primary, Goebbels, Rose-Marie, primary, Mendola, Antonella, primary, Govaerts, Anne-Sophie, primary, Fortpied, Catherine, primary, Baldin, Pamela, primary, Licitra, Lisa F., primary, Lalami, Yassine, primary, Clement, Paul M., primary, Machiels, Jean-Pascal H., primary, and Schmitz, Sandra, primary

Published
2023
Full Text
View/download PDF

21. Role of chemotherapy in 5000 patients with head and neck cancer treated by curative surgery: A subgroup analysis of the meta-analysis of chemotherapy in head and neck cancer

Author

Dauzier, Etienne, Lacas, Benjamin, Blanchard, Pierre, Le, Quynh-Thu, Simon, Christian, Wolf, Gregory, Janot, François, Horiuchi, Masatoshi, Tobias, Jeffrey S., Moon, James, Simes, John, Deshmane, Vinay, Mazeron, Jean-Jacques, Mehta, Samir, Zaktonik, Branko, Tamura, Minoru, Moyal, Elizabeth, Licitra, Lisa, Fortpied, Catherine, Haffty, Bruce G., Ghi, Maria Grazia, Gregoire, Vincent, Harris, Jonathan, Bourhis, Jean, Aupérin, Anne, and Pignon, Jean-Pierre

Published
2019
Full Text
View/download PDF

22. Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma.

Author

Federico, Massimo, Fortpied, Catherine, Stepanishyna, Yana, Gotti, Manuel, van der Maazen, Richard, Cristinelli, Caterina, Re, Alessandro, Plattel, Wouter, Lazarovici, Julien, Merli, Francesco, Specht, Lena, Schiano de Colella, Jean-Marc, Hutchings, Martin, Versari, Annibale, Edeline, Véronique, Stamatoulas, Aspasia, Girinsky, Theodore, Ricardi, Umberto, Aleman, Berthe, and Meulemans, Bart

Published
2024
Full Text
View/download PDF

23. Tumor Microenvironment Modifications Induced by Afatinib in Squamous Cell Carcinoma of the Head and Neck: A Window-of-Opportunity Study (EORTC-90111–24111)

Author

Beyaert, Simon P., primary, Loriot, Axelle E., additional, Huyghe, Nicolas D., additional, Goebbels, Rose-Marie, additional, Mendola, Antonella, additional, Govaerts, Anne-Sophie, additional, Fortpied, Catherine, additional, Baldin, Pamela, additional, Licitra, Lisa F., additional, Lalami, Yassine, additional, Clement, Paul M., additional, Machiels, Jean-Pascal H., additional, and Schmitz, Sandra, additional

Published
2023
Full Text
View/download PDF

24. Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial

Author

Cottereau, Anne-Ségolène, Versari, Annibale, Loft, Annika, Casasnovas, Olivier, Bellei, Monica, Ricci, Romain, Bardet, Stéphane, Castagnoli, Antonio, Brice, Pauline, Raemaekers, John, Deau, Bénédicte, Fortpied, Catherine, Raveloarivahy, Tiana, Van Zele, Emelie, Chartier, Loic, Vander Borght, Thierry, Federico, Massimo, Hutchings, Martin, Ricardi, Umberto, Andre, Marc, and Meignan, Michel

Published
2018
Full Text
View/download PDF

26. Rituximab maintenance improves overall survival of patients with follicular lymphoma—Individual patient data meta-analysis

Author

Vidal, Liat, Gafter-Gvili, Anat, Salles, Gilles, Bousseta, Sami, Oberman, Bernice, Rubin, Carmit, van Oers, Marinus H.J., Fortpied, Catherine, Ghielmini, Michele, Pettengell, Ruth, Witzens-Harig, Mathias, Dreger, Peter, Vitolo, Umberto, Gomes da Silva, Maria, Evangelista, Andrea, Li, Hailun, Freedman, Laurence, Habermann, Thomas M., and Shpilberg, Ofer

Published
2017
Full Text
View/download PDF

27. The association of internal mammary and medial supraclavicular lymph node radiation technique with clinical outcomes

Author

Kaidar-Person, Orit, Fortpied, Catherine, Hol, Sandra, Weltens, Caroline, Kirkove, Carine, Budach, Volker, Peignaux-Casasnovas, Karine, van der Leij, Femke, Vonk, Ernest, Valli, Mariacarla, Weidner, Nicola, Guckenberger, Matthias, Koiter, Eveline, Fourquet, Alain, Bartelink, Harry, Struikmans, Henk, Poortmans, Philip, EORTC Radiation Oncology and Breast Cancer Groups, EORTC Radiation Oncology and Breast Cancer Groups, Radiotherapie, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, UCL - (SLuc) Service de radiothérapie oncologique, University of Zurich, and Kaidar-Person, Orit

Subjects
QUALITY-ASSURANCE, 2720 Hematology, 610 Medicine & health, Breast Neoplasms, HEART-DISEASE, BREAST-CANCER RADIOTHERAPY, THERAPY, Disease-Free Survival, Breast cancer, MASTECTOMY, 2741 Radiology, Nuclear Medicine and Imaging, Humans, Radiology, Nuclear Medicine and imaging, Breast, Thoracic Wall, RECURRENCE, Lymph nodes, Computer. Automation, RISK, Radiotherapy, MORTALITY, WOMEN, Hematology, 10044 Clinic for Radiation Oncology, Quality assurance, Techniques, EORTC, Oncology, 2730 Oncology, Female, CHAIN IRRADIATION, Lymph Nodes, Human medicine
Abstract

BACKGROUND AND PURPOSE: The multicentre EORTC 22922/10925 trial (ClinicalTrials.gov, NCT00002851) was conducted between 1996 and 2004. The trial evaluated the effect of irradiation of the internal mammary and medial supraclavicular lymph node chains (IM-MS) vs no further radiation therapy (RT) on survival and cause of death in breast cancer stage I-III patients. At 15.7 years of median follow-up, a significant reduction of breast cancer specific mortality (BCSM) and any recurrence, not translating in improved overall survival (OS), and low absolute rates of side effects were found. The aim of the current analysis was to evaluate the association of RT techniques of IM-MS lymph node irradiation with long-term outcomes.PATIENTS AND METHODS: Three RT techniques were used for IM-MS: a standard technique using a fixed set-up combining photon/electron beams to the IM and tangential fields to the breast or chest wall vs a standard-modified technique with minor adaptation for beam settings vs a more individualised technique based on individual localisation of the IM. Techniques used were fixed per institution over the duration of the trial. We performed an exploratory and descriptive analysis of the outcomes after 15 years follow-up for the three RT techniques.RESULTS: Between July 1996 and January 2004, 46 radiation oncology departments from 13 countries accrued 4004 patients. Median follow-up was 15.7 years. The number of patients treated by each technique was 2440 (61%) by standard vs 635 (16%) by standard-modified vs 929 (23%) patients by individualised technique. The absolute improvements of oncological outcomes in terms of disease-free survival (DFS), OS and BCSM with IM-MS RT compared to no IM-MS RT were 6.8%, 4.9% and -5.8% for the individualised technique, vs 1.6%, 2.9% and -4.3% for modified standard and -1.4%, 1.1% and -3% for standard technique, respectively. The increase in 15-year rates of side effects due to IM-MS RT, both scored longitudinally and cross-sectionally, were similar among the techniques.CONCLUSION: Even though a straightforward comparison by technique is not possible because of variations in baseline characteristics between institutions, our findings suggest that the use of more individualised RT techniques is associated with higher rates of oncological improvements without increased risks for late side effects.

Published
2022

28. Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials

Author

Maraldo, Maja V, Giusti, Francesco, Vogelius, Ivan R, Lundemann, Michael, van der Kaaij, Marleen A E, Ramadan, Safaa, Meulemans, Bart, Henry-Amar, Michel, Aleman, Berthe M P, Raemaekers, John, Meijnders, Paul, Moser, Elisabeth C, Kluin-Nelemans, Hanneke C, Feugier, Pierre, Casasnovas, Olivier, Fortpied, Catherine, and Specht, Lena

Published
2015
Full Text
View/download PDF

29. Relapse patterns in early‐PET negative, limited‐stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy–a joint analysis of EORTC/LYSA/FIL H10 and NCRI RAPID trials

Author

Fiaccadori, Valeria, primary, Neven, Anouk, additional, Fortpied, Catherine, additional, Aurer, Igor, additional, Andre, Marc, additional, Federico, Massimo, additional, Counsell, Nicholas, additional, Phillips, Elizabeth H., additional, Clifton‐Hadley, Laura, additional, Barrington, Sally F., additional, Illidge, Timothy, additional, Radford, John, additional, and Raemaekers, John M. M., additional

Published
2022
Full Text
View/download PDF

30. T001: FDG-PET and serum TARC levels after one cycle of BV-AVD in advanced stage Hodgkin lymphoma patients: results from the very early PET-response adapted EORTC-COBRA trial

Author

Diepstra, Arjan, primary, Visser, Lydia, additional, Fortpied, Catherine, additional, Noordzij, Walter, additional, Loft, Annika, additional, Arens, Anne, additional, Sureda-Balari, Anna, additional, Carvalho, Susana, additional, Vranovský, Andrej, additional, Sents, Ward, additional, Buhrer, Emanuel, additional, Plattel, Wouter J., additional, and Hutchings, Martin, additional

Published
2022
Full Text
View/download PDF

31. High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline

Author

Rossi, Cédric, primary, André, Marc, additional, Dupuis, Jehan, additional, Morschhauser, Franck, additional, Joly, Bertrand, additional, Lazarovici, Julien, additional, Ghesquières, Hervé, additional, Stamatoullas, Aspasia, additional, Nicolas-Virelizier, Emmanuelle, additional, Feugier, Pierre, additional, Gac, Anne-Claire, additional, Moatti, Hannah, additional, Fornecker, Luc-Matthieu, additional, Deau, Bénédicte, additional, Joubert, Clémentine, additional, Fortpied, Catherine, additional, Raemaekers, John, additional, Federico, Massimo, additional, Kanoun, Salim, additional, Meignan, Michel, additional, Traverse-Glehen, Alexandra, additional, Cottereau, Anne-Ségolène, additional, and Casasnova, René-Olivier, additional

Published
2022
Full Text
View/download PDF

32. High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: TMTV is a useful risk factor to stratify patients at baseline

Author

Rossi, Cédric, André, Marc, Dupuis, Jehan, Morschhauser, Franck, Joly, Bertrand, Lazarovici, Julien, Ghesquières, Hervé, Stamatoullas, Aspasia, Nicolas-Virelizier, Emmanuelle, Feugier, Pierre, Gac, Anne-Claire, Moatti, Hannah, Fornecker, Luc-Matthieu, Deau, Bénédicte, Joubert, Clémentine, Fortpied, Catherine, Raemaekers, John, Federico, Massimo, Kanoun, Salim, Meignan, Michel, Traverse-Glehen, Alexandra, Cottereau, Anne-Ségolène, Casasnovas, René-Olivier, UCL - SSS/IREC/MONT - Pôle Mont Godinne, and UCL - (MGD) Service d'hématologie

Abstract

Stage IIB Hodgkin lymphoma (HL) patients, with a mediastinum-to-thorax (M/T) ratio of ≥0.33 or extranodal localization have a poor prognosis and are treated either as limited or advanced stage. We compared these two approaches in patients included in two randomized phase III trials enrolling previously untreated early (H10) or advanced stage HL (AHL2011). We included HL patients with Ann-Arbor stage IIB with M/T ≥0.33 or extranodal involvement enrolled in the H10 or AHL2011 trials with available PET at baseline and after two cycles of chemotherapy (PET2). Baseline total metabolic tumor volume (TMTV) was calculated using the 41% SUVmax method. PET2 response assessment used the Deauville score. 148 patients were eligible, including 83 enrolled in the AHL2011 trial and 65 in the H10 trial. The median TMTV value was 155.5 mL (8.3-782.9), 165.6 mL in AHL2011 and 147 mL in H10. PET2 positivity rates were 16.9% (n=14) and 9.2% (n=6) in AHL2011 and H10 patients, respectively. With a median follow-up of 4.1 years (95%CI 3.9-4.4), overall 4-year PFS was 88.0%, 87.0% in AHL2011 and 89.2% in H10. In univariate and mutivariate analyses, baseline TMTV and PET2 response influenced significantly PFS (HR=4.94, HR=3.49 respectively). Notably, among the 16 patients who relapsed, 13 (81%) had a baseline TMTV baseline ≥ 155 mL. Upfront ABVD plus radiation therapy or upfront escBEACOPP without radiotherapy provide similar patient's outcome in high-risk stage IIB HL. TMTV is useful to stratify these patients at baseline.

Published
2022

34. Relapse patterns in early‐PET negative, limited‐stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy–a joint analysis of EORTC/LYSA/FIL H10 and NCRI RAPID trials.

Author

Fiaccadori, Valeria, Neven, Anouk, Fortpied, Catherine, Aurer, Igor, Andre, Marc, Federico, Massimo, Counsell, Nicholas, Phillips, Elizabeth H., Clifton‐Hadley, Laura, Barrington, Sally F., Illidge, Timothy, Radford, John, and Raemaekers, John M. M.

Subjects
HODGKIN'S disease, COMBINED modality therapy, POSITRON emission tomography
Abstract

Summary: In the H10 and RAPID randomised trials, chemotherapy+radiotherapy (combined modalities treatment, CMT) was compared with chemotherapy (C) in limited‐stage Hodgkin lymphoma (HL), with negative early positron emission tomography (ePETneg). We analysed patterns of relapses in the H10 trial, validated findings in the RAPID trial and performed a combined analysis stratified by trial. The impact of radiotherapy (RT) on risk of relapse was studied using adjusted Cox models, with time‐varying effects. In H10, 1,059 ePETneg patients were included (465 European Organisation for Research and Treatment of Cancer (EORTC) favourable [F], 594 unfavourable [U]). Among the F patients, 2/227 (1%) relapsed after CMT, 30/238 (13%) after C: of these relapses, 21/30 (70%) occurred in less than 2 years and 25/30 (83%) affected originally involved areas. Among the U group, 16/292 (5%) relapsed after CMT: 8/16 (50%) in less than 2 years, 11/16 (69%) in originally involved areas. After C 30/302 (10%) relapsed: 27/30 (90%) in less than 2 years, and 26/30 (87%) in originally involved areas. Similar results were observed in 419 ePETneg RAPID patients (241 F, 128 U, 50 unclassified): among F patients, 6/118 (5%) relapsed after CMT; 13/123 (11%) after C: 11/13 (85%) in less than 2 years and 11/13 (85%) affecting originally involved areas. In U patients, 3/65 (5%) relapsed after CMT and 5/63 (8%) after C. In both trials, omitting RT in ePETneg HL resulted in more early relapses, mainly affecting originally involved areas. RT significantly reduced risk of early relapses in the combined stratified analysis. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

37. A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial

Author

Galot, Rachel, primary, Le Tourneau, Christophe, additional, Saada-Bouzid, Esma, additional, Daste, Amaury, additional, Even, Caroline, additional, Debruyne, Philip, additional, Henry, Stéphanie, additional, Zanetta, Sylvie, additional, Rutten, Anemie, additional, Licitra, Lisa, additional, Canon, Jean-Luc, additional, Kaminsky, Marie-Christine, additional, Specenier, Pol, additional, Rottey, Sylvie, additional, Guigay, Joël, additional, Kong, Anthony, additional, Tinhofer, Inge, additional, Borcoman, Edith, additional, Dirix, Lieve, additional, Raveloarivahy, Tiana, additional, Fortpied, Catherine, additional, Vanlancker, Maureen, additional, Morfouace, Marie, additional, Govaerts, Anne-Sophie, additional, and Machiels, Jean-Pascal, additional

Published
2021
Full Text
View/download PDF

39. Side effects 15 years after lymph node irradiation in breast cancer : randomized EORTC trial 22922/10925

Author

Poortmans, Philip M, Struikmans, Henk, De Brouwer, Peter, Weltens, Caroline, Fortpied, Catherine, Kirkove, Carine, Budach, Volker, Peignaux-Casasnovas, Karine, van der Leij, Femke, Vonk, Ernest, Valli, Mariacarla, vanTienhoven, Geertjan, Weidner, Nicola, Noel, Georges, Guckenberger, Matthias, Koiter, Eveline, vanLimbergen, Erik, Engelen, Antoine, Fourquet, Alain, Bartelink, Harry, EORTC Radiation Oncology and Breast Cancer Groups, EORTC Radiation Oncology Breast Cancer Groups, UCL - (SLuc) Service de radiothérapie oncologique, UCL - (SLuc) Centre du cancer, UCL - SSS/IREC/SLUC - Pôle St.-Luc, University of Zurich, and Poortmans, Philip M

Subjects
Cancer Research, medicine.medical_specialty, 610 Medicine & health, Breast Neoplasms, Gastroenterology, Breast cancer, Internal medicine, Medicine, Humans, Cumulative incidence, 1306 Cancer Research, Breast, Lymph node, Not evaluated, business.industry, Incidence (epidemiology), Cancer, medicine.disease, Primary tumor, 10044 Clinic for Radiation Oncology, Confidence interval, medicine.anatomical_structure, Oncology, Axilla, 2730 Oncology, Female, Lymph Nodes, Human medicine, business
Abstract

Background Uncertainty about the benefit–risk ratio of regional lymph node irradiation led to varying clinical protocols. We investigated long-term late side effects after internal mammary and medial supraclavicular (IM-MS) lymph node irradiation to improve shared decision making. Methods The multicenter European Organization for Research and Treatment of Cancer trial (ClinicalTrials.gov, NCT00002851) randomly assigned stage I-III breast cancer patients with involved axillary nodes and/or a medially located primary tumor. We analyzed late side effects both longitudinally at every follow-up and cross-sectionally at 5-year intervals. All statistical tests were 2-sided. Results Between 1996 and 2004, 46 departments from 13 countries accrued 4004 patients. Median follow-up was 15.7 years. Longitudinal follow-up data showed cumulative incidence rates at 15 years of 2.9% (95% confidence interval [CI] = 2.2% to 3.8%) vs 5.7% (95% CI = 4.7% to 6.9%) (P < .001) for lung fibrosis, 1.1% (95% CI = 0.7% to 1.7%) vs 1.9% (95% CI = 1.3% to 2.6%) (P = .07) for cardiac fibrosis, and 9.4% (95% CI = 8.0% to 10.8%) vs 11.1% (95% CI = 9.6% to 12.7%) (P = .04) for any cardiac disease when treated without or with IM-MS lymph node irradiation. There was no evidence for differences between left- and right-sided breast cancer (Wald χ2 test of treatment by breast side interaction, P = .33 and P = .35, for cardiac fibrosis and for any cardiac disease, respectively). The cumulative incidence probabilities of cross-sectionally reported side effects with a score of 2 or greater at 15 years were 0.1% (95% CI = 0.0% to 0.5%) vs 0.8% (95% CI = 0.4% to 1.4%) for pulmonary (P = .02), 1.8% (95% CI = 1.1% to 2.8%) vs 2.6% (95% CI = 1.8% to 3.7%) for cardiac (P = .15), and 0.0% (95% CI not evaluated) vs 0.1% (95% CI = 0.0% to 0.4%) for esophageal (P = .16), respectively. No difference was observed in the incidence of second malignancies, contralateral breast cancer, or cardiovascular deaths. Conclusions The incidence of late pulmonary side effects was statistically significantly higher after IM-MS lymph node irradiation, as were some of the cardiac events, without a difference between left- and right-sided treatments. Absolute rates and differences were very low, without increased non-breast cancer–related mortality, even before introducing heart-sparing techniques.

Published
2021

40. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis

Author

Petit, Claire, primary, Lacas, Benjamin, additional, Pignon, Jean-Pierre, additional, Le, Quynh Thu, additional, Grégoire, Vincent, additional, Grau, Cai, additional, Hackshaw, Allan, additional, Zackrisson, Björn, additional, Parmar, Mahesh K B, additional, Lee, Ju-Whei, additional, Ghi, Maria Grazia, additional, Sanguineti, Giuseppe, additional, Temam, Stéphane, additional, Cheugoua-Zanetsie, Maurice, additional, O'Sullivan, Brian, additional, Posner, Marshall R, additional, Vokes, Everett E, additional, Cruz Hernandez, Juan J, additional, Szutkowski, Zbigniew, additional, Lartigau, Eric, additional, Budach, Volker, additional, Suwiński, Rafal, additional, Poulsen, Michael, additional, Kumar, Shaleen, additional, Ghosh Laskar, Sarbani, additional, Mazeron, Jean-Jacques, additional, Jeremic, Branislav, additional, Simes, John, additional, Zhong, Lai-Ping, additional, Overgaard, Jens, additional, Fortpied, Catherine, additional, Torres-Saavedra, Pedro, additional, Bourhis, Jean, additional, Aupérin, Anne, additional, Blanchard, Pierre, additional, Adelstein, D.J., additional, Agarwal, J., additional, Alfonsi, M., additional, Argiris, A., additional, Aupérin, A., additional, Bacigalupo, A., additional, Bar-Ad, V., additional, Bartelink, H., additional, Beadle, B., additional, Belkacemi, Y., additional, Bensadoun, R.J., additional, Bernier, J., additional, Blanchard, P., additional, Bourhis, J., additional, Bratland, Å., additional, Brizel, D., additional, Budach, V., additional, Budach, W., additional, Burtness, B., additional, Calais, G., additional, Campbell, B., additional, Caudell, J., additional, Chabaud, S., additional, Chamorey, E., additional, Chaukar, D., additional, Cheugoua-Zanetsie, M., additional, Cho, K.H., additional, Choussy, O., additional, Cruz Hernandez, J.J., additional, Denham, J.W., additional, Dobrowsky, W., additional, Dominello, M.M, additional, Driessen, C.M.L., additional, Fallai, C., additional, Forastiere, A.A., additional, Fortpied, C., additional, Fountzilas, G., additional, Garaud, P., additional, Garden, A.S., additional, Gery, B., additional, Ghadjar, P., additional, Ghi, M.G., additional, Ghosh Laskar, S., additional, Graff-Cailleaud, P., additional, Grau, C., additional, Gregoire, V., additional, Hackshaw, A., additional, Haddad, E, additional, Haffty, B.G., additional, Hansen, A., additional, Hay, J.H., additional, Hayoz, S., additional, Horiot, J.C., additional, Hitt, R., additional, Jeremic, B., additional, Johansen, J., additional, Jones, C., additional, Julieron, M., additional, Kristensen, C.A., additional, Kumar, S., additional, Lacas, B., additional, Langendijk, J.A., additional, Lapeyre, M., additional, Lartigau, E., additional, Licitra, L., additional, Le, Q.T., additional, Lee, J.W., additional, Lee, P., additional, Lewin, F., additional, Li, Y., additional, Lopes, A., additional, Lotayef, M., additional, Maciejewski, B., additional, Mazeron, J.J., additional, Mehta, S., additional, Michalski, W., additional, Moon, J., additional, Moon, S.H., additional, Moyal, E., additional, Nankivell, M., additional, Nilsson, P., additional, Olmi, P., additional, Orecchia, R., additional, O'Sullivan, B., additional, Overgaard, J., additional, Parmar, M.K.B., additional, Petit, C., additional, Pignon, J.P., additional, Pointreau, Y., additional, Posner, M.R., additional, Poulsen, M.G., additional, Quon, H., additional, Racadot, S., additional, Rosenthal, D.I., additional, Rovea, P., additional, Ruo Redda, M.G., additional, Sanguineti, G., additional, Shenouda, G., additional, Simes, J., additional, Sharma, A., additional, Simon, C., additional, Sire, C., additional, Skladowski, K., additional, Spencer, S., additional, Staar, S., additional, Strojan, P., additional, Stromberger, C., additional, Suwinski, R., additional, Szutkowski, Z., additional, Takácsi-Nagy, Z., additional, Tao, Y.G., additional, Temam, S., additional, Thomson, D., additional, Tobias, J.S., additional, Torres-Saavedra, P., additional, Torri, V., additional, Tripcony, L., additional, Trotti, A., additional, Tseroni, V., additional, van Herpen, C., additional, van Tinteren, H., additional, Vermorken, J., additional, Viegas, C.M.P., additional, Vokes, E.E., additional, Waldron, J., additional, Wernecke, K.D, additional, Widder, J., additional, Wolf, G.T., additional, Wong, S.J., additional, Wu, J.S., additional, Yamazaki, H., additional, Zaktonik, B., additional, Zackrisson, B., additional, and Zhong, L.P., additional

Published
2021
Full Text
View/download PDF

41. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group

Author

Lacas, Benjamin, primary, Carmel, Alexandra, additional, Landais, Cécile, additional, Wong, Stuart J., additional, Licitra, Lisa, additional, Tobias, Jeffrey S., additional, Burtness, Barbara, additional, Ghi, Maria Grazia, additional, Cohen, Ezra E.W., additional, Grau, Cai, additional, Wolf, Gregory, additional, Hitt, Ricardo, additional, Corvò, Renzo, additional, Budach, Volker, additional, Kumar, Shaleen, additional, Laskar, Sarbani Ghosh, additional, Mazeron, Jean-Jacques, additional, Zhong, Lai-Ping, additional, Dobrowsky, Werner, additional, Ghadjar, Pirus, additional, Fallai, Carlo, additional, Zakotnik, Branko, additional, Sharma, Atul, additional, Bensadoun, René-Jean, additional, Ruo Redda, Maria Grazia, additional, Racadot, Séverine, additional, Fountzilas, George, additional, Brizel, David, additional, Rovea, Paolo, additional, Argiris, Athanassios, additional, Nagy, Zoltán Takácsi, additional, Lee, Ju-Whei, additional, Fortpied, Catherine, additional, Harris, Jonathan, additional, Bourhis, Jean, additional, Aupérin, Anne, additional, Blanchard, Pierre, additional, Pignon, Jean-Pierre, additional, Adelstein, D.J., additional, Alfonsi, M., additional, Belkacemi, Y., additional, Bar-Ad, V., additional, Bernier, J., additional, Bratland, Å., additional, Calais, G., additional, Campbell, B., additional, Caudell, J., additional, Chabaud, S., additional, Chamorey, E., additional, Chaukar, D., additional, Choi, K.N., additional, Choussy, O., additional, Collette, L., additional, Cruz, J.J., additional, Dani, C., additional, Dauzier, E., additional, Forastiere, A.A., additional, Garaud, P., additional, Gregoire, V., additional, Hackshaw, A., additional, Haddad, E., additional, Haffty, B.G., additional, Hansen, A., additional, Hayoz, S., additional, Horiot, J.C., additional, Jeremic, B., additional, Karrison, T.G., additional, Langendijk, J.A., additional, Lapeyre, M., additional, Lartigau, E., additional, Leong, T., additional, Le, Q.T., additional, Lee, P.P.Y., additional, Lewin, F., additional, Lin, A., additional, Lopes, A., additional, Mehta, S., additional, Moon, J., additional, Moyal, E., additional, Occéan, B.V., additional, Olmi, P., additional, Orecchia, R., additional, O'Sullivan, B., additional, Overgaard, J., additional, Petit, C., additional, Quon, H., additional, Sanguineti, G., additional, Satar, T., additional, Simes, J., additional, Simon, C., additional, Sire, C., additional, Staar, S., additional, Stromberger, C., additional, Strojan, P., additional, Temam, S., additional, Thomson, D., additional, Timochenko, A., additional, Torri, V., additional, Tseroni, V., additional, Vermorken, J., additional, Vokes, E.E., additional, Waldron, J., additional, Wernecke, K.D., additional, Widder, J., additional, and Zackrisson, B., additional

Published
2021
Full Text
View/download PDF

43. Long‐term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials

Author

André, Marc P. E., primary, Carde, Patrice, additional, Viviani, Simonetta, additional, Bellei, Monica, additional, Fortpied, Catherine, additional, Hutchings, Martin, additional, Gianni, Alessandro M., additional, Brice, Pauline, additional, Casasnovas, Olivier, additional, Gobbi, Paolo G., additional, Zinzani, Pier Luigi, additional, Dupuis, Jehan, additional, Iannitto, Emilio, additional, Rambaldi, Alessandro, additional, Brière, Josette, additional, Clément‐Filliatre, Laurianne, additional, Heczko, Marian, additional, Valagussa, Pinuccia, additional, Douxfils, Jonathan, additional, Depaus, Julien, additional, Federico, Massimo, additional, and Mounier, Nicolas, additional

Published
2020
Full Text
View/download PDF

44. Stage IIb High Risk Hodgkin Lymphoma Treated in the H10 and AHL2011 Trials: Similar Efficacy of Both Strategies and Prognostic Impact of Baseline Tmtv and PET2 Response

Author

Rossi, Cédric, primary, André, Marc, primary, Joubert, Clémentine, primary, Fortpied, Catherine, primary, Brice, Pauline, primary, Deau-Fisher, Bénédicte, primary, Ghesquieres, Herve, primary, Fornecker, Luc Mathieu, primary, Gac, Anne-Claire, primary, Lazarovici, Julien, primary, Stamatoullas, Aspasia, primary, Raemakers, John, primary, Federico, Massimo, primary, Maerevoet, Marie, primary, Bailly, Sarah, primary, Kanoun, Salim, primary, Meignan, Michel, primary, Cottereau, Anne Ségolène, primary, and Casasnovas, Rene-Olivier, primary

Published
2019
Full Text
View/download PDF

45. Organ Preservation and Late Functional Outcome in Oropharyngeal Carcinoma: Rationale of EORTC 1420, the “Best of” Trial

Author

Stelmes, Jean-Jacques, primary, Gregoire, Vincent, additional, Poorten, Vincent Vander, additional, Golusiñski, Wojciech, additional, Szewczyk, Mateusz, additional, Jones, Terry, additional, Ansarin, Mohssen, additional, Broglie, Martina A., additional, Giger, Roland, additional, Klussmann, Jens Peter, additional, Evans, Mererid, additional, Bourhis, Jean, additional, Leemans, C. René, additional, Spriano, Giuseppe, additional, Dietz, Andreas, additional, Hunter, Keith, additional, Zimmermann, Frank, additional, Tinhofer, Ingeborg, additional, Patterson, Joanne M., additional, Quaglini, Silvana, additional, Govaerts, Anne-Sophie, additional, Fortpied, Catherine, additional, and Simon, Christian, additional

Published
2019
Full Text
View/download PDF

46. Reference values for the EORTC QLQ‐C30 in patients with advanced stage Hodgkin lymphoma and in Hodgkin lymphoma survivors.

Author

Vachon, Hugo, Mierzynska, Justyna, Taye, Mekdes, Pe, Madeline, Coens, Corneel, Martinelli, Francesca, Fortpied, Catherine, Flechtner, Hans‐Henning, Vestmoe Maraldo, Maja, Hutchings, Martin, Meijnders, Paul, Aleman, Berthe, Lugtenburg, Pieternella, Spina, Michele, André, Marc, Hertzberg, Mark, Briones, Javier, and Bottomley, Andrew

Subjects
HODGKIN'S disease, REFERENCE values, QUALITY of life
Abstract

Objectives: To provide reference values for the European Organisation for Treatment and Research of Cancer (EORTC) Quality of Life Questionnaire (QLQ‐C30) in advanced‐stage Hodgkin lymphoma (HL) patients and 5‐year HL survivors. The QLQ‐C30 is the most widely used cancer‐specific questionnaire to assess Health‐Related Quality of Life (HRQoL). Methods: The EORTC database was searched to identify HL RCTs in which patients' and survivors' HRQoL was assessed by the QLQ‐C30. HRQoL mean scores were calculated and stratified by age and gender. Minimal important differences were used to assess the clinical relevance of the findings. Data from one RCT with HRQoL scores available at baseline (n = 343) and four RCTs with HRQoL scores available at follow‐up (n = 1665) were analyzed. Results: Patients reported worse HRQoL scores than survivors across most functioning scales and symptoms' scales. These scores varied as a function of gender but not age. Survivors' HRQoL reports were comparable to the ones of the general population. Conclusions: These values provide an assessment framework for the comparison and interpretation of QLQ‐C30 scores in advanced‐stage HL. Our findings suggest that although HL patients' HRQoL scores are worse than the general population, HRQoL scores may normalize over long‐term survival. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

48. Predictive Classifier for Intensive Treatment of Head and Neck Cancer

Author

Zakeri, Kaveh, primary, Rotolo, Federico, additional, Lacas, Benjamin, additional, Vitzthum, Lucas K., additional, Le, Quynh-Thu, additional, Gregoire, Vincent, additional, Overgaard, Jens, additional, Hackshaw, Allan, additional, Zackrisson, Björn, additional, Parmar, Mahesh K.B., additional, Burtness, Barbara, additional, Ghi, Maria Grazia, additional, Sanguineti, Giuseppe, additional, O’Sullivan, Brian, additional, Fortpied, Catherine, additional, Bourhis, Jean, additional, Shen, Hanjie, additional, Harris, Jonathan, additional, Michiels, Stefan, additional, Pignon, Jean-Pierre, additional, Mell, Loren, additional, Group, MARCH/MACH-NC Collaborative, additional, and (HNCIG), the Head and Neck Cancer Intergroup, additional

Published
2019
Full Text
View/download PDF

49. Prognostic Value of Immunohistochemical Markers in Stage III/IV Classical Hodgkin Lymphoma Treated Frontline in the Lysa EORTC 20012 Randomized Protocol

Author

Canioni, Danielle, primary, Brice, Pauline, additional, Bologna, Serge, additional, Voillat, Laurent, additional, Gabarre, Jean, additional, Casasnovas, Olivier, additional, Devidas, Alain, additional, Coiffier, Bertrand, additional, Aoudjhane, Malek, additional, Audhuy, Bruno, additional, Andre, Marc, additional, Fortpied, Catherine, additional, Carde, Patrice, additional, Mounier, Nicolas, additional, and Briere, Josette, additional

Published
2018
Full Text
View/download PDF

50. Predictive classifier for intensive treatment of head and neck cancer.

Author

Zakeri, Kaveh, Rotolo, Federico, Lacas, Benjamin, Vitzthum, Lucas K., Le, Quynh‐Thu, Gregoire, Vincent, Overgaard, Jens, Hackshaw, Allan, Zackrisson, Björn, Parmar, Mahesh K. B., Burtness, Barbara A., Ghi, Maria Grazia, Sanguineti, Giuseppe, O'Sullivan, Brian, Fortpied, Catherine, Bourhis, Jean, Shen, Hanjie, Harris, Jonathan, Michiels, Stefan, and Pignon, Jean‐Pierre

Subjects
HEAD & neck cancer, MOUTH, TREATMENT effectiveness, SQUAMOUS cell carcinoma, CANCER invasiveness
Abstract

Background: This study was designed to test the hypothesis that the effectiveness of intensive treatment for locoregionally advanced head and neck cancer (LAHNC) depends on the proportion of patients' overall event risk attributable to cancer.Methods: This study analyzed 22,339 patients with LAHNC treated in 81 randomized trials testing altered fractionation (AFX; Meta-Analysis of Radiotherapy in Squamous Cell Carcinomas of Head and Neck [MARCH] data set) or chemotherapy (Meta-Analysis of Chemotherapy in Head and Neck Cancer [MACH-NC] data set). Generalized competing event regression was applied to the control arms in MARCH, and patients were stratified by tertile according to the ω score, which quantified the relative hazard for cancer versus competing events. The classifier was externally validated on the MACH-NC data set. The study tested for interactions between the ω score and treatment effects on overall survival (OS).Results: Factors associated with a higher ω score were a younger age, a better performance status, an oral cavity site, higher T and N categories, and a p16-negative/unknown status. The effect of AFX on OS was greater in patients with high ω scores (hazard ratio [HR], 0.92; 95% confidence interval [CI], 0.85-0.99) and medium ω scores (HR, 0.91; 95% CI, 0.84-0.98) versus low ω scores (HR, 0.97; 95% CI, 0.90-1.05; P for interaction = .086). The effect of chemotherapy on OS was significantly greater in patients with high ω scores (HR, 0.81; 95% CI, 0.75-0.88) and medium ω scores (HR, 0.86; 95% CI, 0.78-0.93) versus low ω scores (HR, 0.96; 95% CI, 0.86-1.08; P for interaction = .011).Conclusions: LAHNC patients with a higher risk of cancer progression relative to competing mortality, as reflected by a higher ω score, selectively benefit from more intensive treatment. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results